BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 23157735)

  • 1. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia.
    Park SY; Park HJ; Moon SM; Park KH; Chong YP; Kim MN; Kim SH; Lee SO; Kim YS; Woo JH; Choi SH
    BMC Infect Dis; 2012 Nov; 12():308. PubMed ID: 23157735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy.
    Kim YJ; Jun YH; Kim YR; Park KG; Park YJ; Kang JY; Kim SI
    BMC Infect Dis; 2014 Mar; 14():161. PubMed ID: 24655422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.
    Bowers DR; Liew YX; Lye DC; Kwa AL; Hsu LY; Tam VH
    Antimicrob Agents Chemother; 2013 Mar; 57(3):1270-4. PubMed ID: 23263001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.
    Chamot E; Boffi El Amari E; Rohner P; Van Delden C
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2756-64. PubMed ID: 12936970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cohort study of bacteremic pneumonia: The importance of antibiotic resistance and appropriate initial therapy?
    Guillamet CV; Vazquez R; Noe J; Micek ST; Kollef MH
    Medicine (Baltimore); 2016 Aug; 95(35):e4708. PubMed ID: 27583907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia.
    Recio R; Viedma E; González-Bodí S; Villa J; Orellana MÁ; Mancheño-Losa M; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2021 Dec; 58(6):106450. PubMed ID: 34644604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
    Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.
    Paulsson M; Granrot A; Ahl J; Tham J; Resman F; Riesbeck K; Månsson F
    Eur J Clin Microbiol Infect Dis; 2017 Jul; 36(7):1187-1196. PubMed ID: 28110415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.
    Peña C; Suarez C; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Oliver A; Martínez-Martínez L;
    Clin Infect Dis; 2013 Jul; 57(2):208-16. PubMed ID: 23580739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Community-acquired Pseudomonas aeruginosa bacteremic pneumonia in a "healthy" subject].
    Illinger J; Mohammedi I; Martin O; Argaud L; St Denis M; Robert D
    Presse Med; 2003 Jul; 32(24):1123. PubMed ID: 12947742
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
    Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
    Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
    Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
    Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for treatment of Pseudomonas aeruginosa bloodstream infections.
    Tschudin-Sutter S; Fosse N; Frei R; Widmer AF
    PLoS One; 2018; 13(9):e0203295. PubMed ID: 30235247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
    Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
    BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa bacteremia upon hospital admission: risk factors for mortality and influence of inadequate empirical antimicrobial therapy.
    Schechner V; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Finkelstein R; Lachish T; Wiener-Well Y; Alon D; Chowers M; Bardenstein R; Zimhony O; Paz A; Potasman I; Giladi M; Schwaber MJ; Klarfeld-Lidji S; Hochman M; Marchaim D; Carmeli Y
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):38-45. PubMed ID: 21763093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacteremic pneumonia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters.
    Cheng WL; Hsueh PR; Lee CC; Li CW; Li MJ; Chang CM; Lee NY; Ko WC
    J Microbiol Immunol Infect; 2016 Apr; 49(2):208-15. PubMed ID: 25070279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.
    Traugott KA; Echevarria K; Maxwell P; Green K; Lewis JS
    Pharmacotherapy; 2011 Jun; 31(6):598-608. PubMed ID: 21923444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bacteremic pneumonia in neutropenic patients with cancer: causes, empirical antibiotic therapy, and outcome.
    Carratalà J; Rosón B; Fernández-Sevilla A; Alcaide F; Gudiol F
    Arch Intern Med; 1998 Apr; 158(8):868-72. PubMed ID: 9570172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and outcome of Pseudomonas aeruginosa bacteremia among adults visiting the ED.
    Lee CC; Lee CH; Hong MY
    Am J Emerg Med; 2012 Jul; 30(6):852-60. PubMed ID: 21855263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.